An observational study in Systemic Lupus Erythematosus, Systemic Scleroderma and ANCA-associated Vasculitis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University Hospital, Strasbourg, France · Observational
Among 168 studies in Lupus Erythematosus, Systemic with a site in France — 43 open to participants now, 62 under way, 20 of them phase 3. Lupus Erythematosus, Systemic · France.
Among the 168 studies in Lupus Erythematosus, Systemic with a site in France, this one is the 25th largest by planned enrollment of the 48 observational ones that give a count, is one of 14 that started in 2026, is one of 48 observational ones, reaches primary completion later than 54 of the 61 other live ones, and was the 156th registered.
1,208 studies on the registry are indexed under Lupus Erythematosus, Systemic; 404 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →43 of the 168 studies in Lupus Erythematosus, Systemic with a site in France are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in France, Australia, Brazil and 3 more countries
Ages 18–75
AstraZeneca · Sites in France, United States, Argentina and 32 more countries
Ages 5–80
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18+
AstraZeneca · Sites in France, United States, Canada and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 283 Lupus Erythematosus, Systemic studies recruiting now, 92 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 39 · Phase 3 46 · Phase 4 3
First in 2004; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 150 across 281 observational studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 174 across the 120 interventional studies, 212 across the 48 observational. Of the 97 that completed or were terminated, 39 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 168 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
University Hospital, Strasbourg, France has 6 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
19 of the studies in Lupus Erythematosus, Systemic with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05458622Phase 3University Hospital, Brest3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol | 2026-11 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT05624749Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | 2027-04-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 168 studies in Lupus Erythematosus, Systemic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase. Many AIDs are linked to the emergence of autoreactive B cells (BCs) directed against components of the self. In healthy individuals, these autoreactive B cells are counter-selected or regulated before reaching the antibody-secreting cell compartment. However, in predisposed individuals, a breakdown in B cell tolerance can occur, leading to the formation of autoantibodies with devastating consequences, such as the emergence of systemic lupus erythematosus (SLE), rheumatoid arthritis, and vasculitis. B-cell depletion is often beneficial in these patients, but paradoxically, therapies targeting B cells are not always effective. Furthermore, B cell depletion via LB-specific antibodies (anti-CD20) or treatment with CD19 chimeric antigen receptor T cells (CAR T) leads to complete and prolonged depression of the entire B compartment without targeting the LB population responsible for the onset of the disease. To date, two pitfalls in studies of human autoreactive LBs often complicate the interpretation of results:
i) the difficulty of identifying autoreactive LBs among all LBs, ii) demonstrating the pathogenicity of autoreactive B lymphocytes when they can be identified individually. We propose to quantify and phenotype these autoreactive/pathogenic B cells using high-throughput flow cytometry in several clinical situations.
Hôpitaux Universitaires de Strasbourg
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: blood draw
Biological: blood draw
Biological: blood draw
Biological: blood draw
Biological: blood draw
blood draw
Study of the percentage of autoreactive LB / tetrameric LB+
Time frame: inclusion visit
Started Jan 2026 (actual). Primary completion is estimated for Dec 2031, 71 months after the start.
Of 90 non-industry observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 212. This study's planned 71 months is above that.
Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 34 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
University Hospital, Strasbourg, France →